Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
Public ClinicalTrials.gov record NCT00003264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Evaluation of Weekly Cisplatin and Gemcitabine in the Treatment of Advanced (Recurrent or Metastatic) Carcinoma of the Head and Neck
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin plus gemcitabine in treating patients with advanced squamous cell head and neck cancer that cannot be treated by surgery or radiation therapy.
Study identification
- NCT ID
- NCT00003264
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1997 (Type not available)
- Primary completion
- Feb 2002 (Actual)
- Completion
- Jun 2002 (Actual)
- Last update posted
- Apr 17, 2013
1997 – 2002
United States locations
- U.S. sites
- 12
- U.S. states
- 2
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hunterdon Regional Cancer Center | Flemington | New Jersey | 08822 | — |
| Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County | Mount Holly | New Jersey | 08060 | — |
| Riverview Medical Center - Booker Cancer Center | Red Bank | New Jersey | 07701 | — |
| St. Francis Medical Center | Trenton | New Jersey | 08629 | — |
| St. Luke's Network - Bethlehem | Bethlehem | Pennsylvania | 18015 | — |
| Delaware County Memorial Hospital | Drexel Hill | Pennsylvania | 19026 | — |
| Harrisburg Polyclinic Medical Center | Harrisburg | Pennsylvania | 17101 | — |
| Saint Mary Regional Center | Langhorne | Pennsylvania | 19047 | — |
| North Penn Hospital | Lansdale | Pennsylvania | 19446-1200 | — |
| Paoli Memorial Hospital | Paoli | Pennsylvania | 19301-1792 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Reading Hospital and Medical Center | Reading | Pennsylvania | 19612-6052 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 17, 2013 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00003264 live on ClinicalTrials.gov.